Renal fibrosis can be reversed by bypassing G2/M arrest with a p53 inhibitor, suggesting that the cell cycle is a key target for the treatment of CKD.[39] It has been found that irbesartan regulates the cell cycle by antagonizing AT1R, thus inhibiting the proliferation of breast cancer cells.[40] Studies have shown that hypertrophy is an important pathological feature of renal diseases such as diabetic nephropathy. Here, TP53 is linked to kidney disorder.